Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), NCR3 agonists(natural cytotoxicity triggering receptor 3 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | CN | 20 Oct 2022 |